- Understand the rationale for potential discontinuation of multiple sclerosis (MS) disease-modifying therapies (DMTs) as people age
- Describe the main efficacy outcomes of the DISCOMS trial
- Use this information to help MS patients make informed decisions about the risks and benefits of continuing or discontinuing DMTs as they age.
11/17/2022 - 7:30am to 8:30am CST
Add to calendar:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Dr. John Corboy